SCHEMBL143213

SCHEMBL143213

Cc1cc(C(=O)NCCCN2CCCC2)c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4cccc(Cl)c4)cc32)[nH]1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 12/20 0.48
KDR P35968 9/20 0.48
PDGFRB P09619 8/20 0.48
FGFR1 P11362 8/20 0.48
LCK P06239 7/20 0.48
YES1 P07947 7/20 0.48
MET P08581 5/20 0.48
CDK2 P24941 2/20 0.48
PTK2B Q14289 2/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
PLK4 O00444 1/20 0.48
RIOK3 O14730 1/20 0.48
CASK O14936 1/20 0.48
GAK O14976 1/20 0.48
DCLK1 O15075 1/20 0.48
EPHB6 O15197 1/20 0.48
MAP3K13 O43283 1/20 0.48
MAP3K7 O43318 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL143687 0.93 SRC (0.49) SRCKDRPDGFRBFGFR1LCK
SCHEMBL142865 0.88 KDR (0.41) SRCKDRPDGFRBFGFR1LCK
SCHEMBL145575 0.86 PDGFRB (0.50) SRCKDRPDGFRBFGFR1LCK
SCHEMBL142633 0.85 KDR (0.66) SRCKDRPDGFRBFGFR1LCK
SCHEMBL6523443 0.83 RET (0.49) SRCKDRPDGFRBFGFR1LCK
SCHEMBL144114 0.80 AURKA (0.44) SRCKDRPDGFRBFGFR1LCK
SCHEMBL142619 0.79 KDR (0.69) SRCKDRPDGFRBFGFR1LCK
SCHEMBL143688 0.78 SRC (0.53) SRCKDRPDGFRBFGFR1LCK
SCHEMBL143611 0.77 MET (0.48) SRCKDRPDGFRBFGFR1LCK
SCHEMBL140610 0.77 KDR (0.70) SRCKDRPDGFRBFGFR1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR VERVA PHARMACEUTICALS PTY LTD (AU) 2012-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR FGF1, FABP4, FGF2 SRC 2611/4885KDR 1077/4885PDGFRB 467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.